NEJM August 2026 Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer

This clinical study investigates the effectiveness of selpercatinib, a targeted drug that blocks the RET protein, as a follow-up treatment for patients with early-stage lung cancer who have already undergone surgery or radiation. Researchers conducted a rigorous trial comparing this medication to a placebo to determine if it could prevent the disease from returning in patients with specific genetic markers. The findings demonstrate that selpercatinib significantly extends event-free survival, drastically reducing the likelihood of cancer recurrence or death compared to those who did not receive the drug. While the treatment carries some risks of side effects involving liver enzymes, its ability to improve long-term outcomes suggests a powerful new strategy for managing early-stage respiratory malignancies.